Development of a reactive oxygen species (ROS)-responsive nanoplatform for targeted oral cancer therapy

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Oral cancer poses a significant therapeutic challenge, necessitating advanced drug delivery systems (DDS).
• Current DDS often lack targeted delivery and responsiveness to the tumor microenvironment, limiting efficacy and increasing side effects.

Purpose of the Study:

• To develop a novel, targeted, and reactive oxygen species (ROS)-triggered nanoplatform for enhanced oral cancer therapy.
• To evaluate the efficacy and safety of this nanoplatform loaded with doxorubicin (DOX) and alpha-tocopherol succinate (alpha-TOS) in oral cancer models.

Main Methods:

• Synthesis of a RGD-PEG-TK-PLGA polymer nanoplatform incorporating a ROS-sensitive linker (TK).
• Characterization of nanoplatform stability, targeting ability, ROS sensitivity, and biocompatibility.
• In vitro evaluation of cellular uptake and inhibition of Cal27 oral cancer cells loaded with DOX and alpha-TOS.
• In vivo assessment of therapeutic efficacy and toxicity in mouse tumor models.

Main Results:

• The RGD-PEG-TK-PLGA nanoplatform demonstrated high stability, excellent targeting, ROS sensitivity, and biocompatibility.
• Nanoparticles (NPs) loaded with DOX and alpha-TOS exhibited enhanced cellular uptake and significant inhibition of Cal27 oral cancer cells.
• In vivo studies showed no toxicity in mice and a significant improvement in therapeutic efficacy against oral tumors.

Conclusions:

• The developed RGD-PEG-TK-PLGA polymeric NP platform is a promising DDS for oral cancer chemotherapy.
• Its targeted and ROS-triggered nature, combined with effective drug loading, offers a potent strategy for improving treatment outcomes.